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Abstract
Plasmodium falciparum infection can cause microvascular dysfunction, cerebral encephalopathy and death if untreated. We have previously shown that high concentrations of free
heme, and C-X-C motif chemokine 10 (CXCL10) in sera of malaria patients induce apoptosis in microvascular endothelial and neuronal cells contributing to vascular dysfunction,
blood-brain barrier (BBB) damage and mortality. Endothelial progenitor cells (EPC) are
microvascular endothelial cell precursors partly responsible for repair and regeneration of
damaged BBB endothelium. Studies have shown that EPC’s are depleted in severe malaria
patients, but the mechanisms mediating this phenomenon are unknown. Toll-like receptors
recognize a wide variety of pathogen-associated molecular patterns generated by pathogens such as bacteria and parasites. We tested the hypothesis that EPC depletion during
malaria pathogenesis is a function of heme-induced apoptosis mediated by CXCL10 induction and toll-like receptor (TLR) activation. Heme and CXCL10 concentrations in plasma
obtained from malaria patients were elevated compared with non-malaria subjects. EPC
numbers were significantly decreased in malaria patients (P < 0.02) and TLR4 expression
was significantly elevated in vivo. These findings were confirmed in EPC precursors in vitro;
where it was determined that heme-induced apoptosis and CXCL10 expression was TLR4mediated. We conclude that increased serum heme mediates depletion of EPC during
malaria pathogenesis.
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Introduction
Plasmodium falciparum infections are responsible for about 283 million malaria cases and
584,000 deaths annually, primarily in Sub Saharan Africa [1]. Approximately 30% of malaria
related deaths occur in children under five years of age despite appropriate treatment, and it is
estimated that a child dies from malaria complications every minute [2, 3]. Current malaria
treatments target malaria parasite but offer limited protection to a subset (10–30%) of patients
who die from severe malaria complications [4, 5]. Adjunctive therapies are urgently needed to
offset these unacceptably high mortality rates.
Malaria mortality is associated with exaggerated host responses to inflammatory factors such
as interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), free heme, C-X-C motif chemokine 10 (CXCL10) and parasite-derived cytotoxins [6–11]. Extensive hemolysis and increased
plasma heme leads to vascular activation, inflammation and over production of CXCL10, which
exacerbates the disease [8, 12, 13]. Previous studies indicate that increased serum levels of free
heme and CXCL10 limited the ability of the host to repair and regenerate damaged blood-brain
barrier (BBB) components during development of severe malaria pathogenesis and were predictive of poor prognosis of severe malaria [14]. In addition, studies indicate that endothelial progenitor cell (EPC) depletion and Toll-like receptors (TLR) 4 and 9 play an important role in
malaria prognosis. EPCs and EPC-precursors are hematopoietic stem and progenitor cells
expressing cluster of differentiation 34 (CD34). CD34 is a hematopoietic progenitor cell antigen
associated with cell-cell adhesion and stem cell attachment, and a subset of CD34+ cells is capable
of differentiating into microvascular endothelial cells (Fig 1) [15–18]. CD34+ hematopoietic stem
and progenitor cells (CD34+-HSPC) are also blood-cell precursors of T- and B-lymphocytes,
which are potently activated by microvascular damage and alterations in chemokine/cytokine
expression [19–21]. In 2014, Belcher et al. found that heme-induced cytotoxicity involves the
TLR4 signaling pathway in sickle cell disease, and may or may not be different than lipopolysaccharide-mediated TLR4 signaling [22, 23]. By-products of this signaling pathway result in
increased expression of the heme-degrading enzyme, heme-oxygenase-1 (HO-1), CXCL10 and
adhesion molecules such as vascular and intercellular cell adhesion molecules [12, 23, 24].
Recent reports have associated decreased circulating EPC with poor prognosis of severe
malaria [25]. Understanding the mechanism involved in EPC depletion in malaria pathogenesis may provide a basis for development of therapies that would protect and retain the EPC
function during malaria treatment or management.
The objective of this study was to determine the effects of free heme on EPC, characterized
as CD45-CD34+VEGFR2+ cells in vivo, and the EPC precursor population, CD34+ hematopoietic stem and progenitor cells, characterized as CD34+-HSPC in vitro. CXCL10 and TLR4
expression in these cells were assessed after exposure to heme at different, physiologically relevant concentrations (10–60 μM). We hypothesized that CD34+-HSPC depletion during
malaria pathogenesis is a function of heme-induced apoptosis mediated by induction of
CXCL10 and TLR activation. Here, we report that free heme activates TLR4 expression and
induces over production of CXCL10 resulting in apoptosis and decreased bioavailability of
EPC and HSPC precursors.

Materials
Reagents and Antibodies
Heme was purchased from Frontier Scientific (Logan, UT). Camptothecin (CPT) and Lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, MS), TLR4 inhibitor/
antagonists monoclonal anti-CD14 antibody and Ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)
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Fig 1. Hematopoietic Stem and Progenitor Cell Populations (HSPC) are vital to vascular endothelial repair and regeneration. HSPC are CD34+ cells
derived from the bone marrow, where they reside in the stromal layer until mobilized in response to chemokines and cytokines released from dysfunctional
endothelium. In the peripheral blood, they are capable of differentiating into endothelial progenitor cells (EPC) that will home into cites of vascular
dysfunction. The EPC retains the hematopoietic surface marker CD34 in addition to gaining the vascular endothelial cell surface marker CD309 or VEGFR2.
These cells will differentiate into mature and circulating endothelial cells capable of incorporating into sites of compromised vasculature, and inducing
neovascularization as well as proliferation of existing endothelial cells.
doi:10.1371/journal.pone.0142328.g001

sulfamoyl] cyclohex-1-ene-1 -carboxylate, (Takeda, TAK-242) were purchased from InvivoGen (San Diego, CA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
was purchased from Life Technologies (Grand Island, NY).

Cell Lines
Human brain microvascular endothelial cell line (HBVEC; Biowhittaker, Walkersville, MD)
was graciously provided by Dr. Bond’s laboratory at Morehouse School of Medicine. Their
characteristics include expression of endothelial lineage markers VEGFR2, von Willebrand factor, CXCL10 and corresponding receptor CXCR3. Primary human CD34+ hematopoietic stem
and progenitor cells (CD34+-HSPC) isolated from human bone marrow obtained from StemCell Technologies, Vancouver, Canada.

Methods
Ethical considerations
All study subjects were enrolled after written informed consent was obtained from them or
their guardians. Informed consent and human subject research guidelines of the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC) in the
United States were followed. The IRB committees at Morehouse School of Medicine (USA)
and the University of Ghana approved this study.

Study sites and population
The study participants were recruited from the Greater Accra region which accounts for 4% of
all malaria cases among children under 5 years and 27% of all outpatient department (OPD)
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malaria cases in Ghana [26]. The study samples were obtained from two study sites: Korle-Bu
Teaching Hospital (KBTH) and the Shai-Osudoku District Hospital (SODH). KBTH is the
leading referral and teaching hospital of the University of Ghana Medical School, which serves
patients from diverse communities in the country. SODH is a district hospital serving the ShaiOsudoku District in Southeastern Ghana. Malaria is endemic and perennial in Ghana, with
seasonal variations that are more pronounced in the northern region [26]. Malaria is the number one cause of morbidity and mortality in the country, accounting for approximately 38% of
all OPD attendance, 36% of all admissions, and 33.4% of all mortality in children less than five
years of age [27]. P. falciparum is the most prevalent in the country with occasional mixed
infection with P. malariae [26].

Enrollment criteria
Malaria patients. Malaria patients with both confirmed thick film slides and Plasmodium
Lactate Dehydrogenase/Histidine Rich Protein-2 (pLDH/HRP-2) Antigen Combo Card rapid
diagnostic test (RDT; BestNet, London, UK) were recruited into the study after informed consent. Parasitemia was evaluated microscopically on the number of parasites per field (+, 1–10
parasites/100 fields, ++, > 10 parasites/100 fields, +++, 1–10 parasites/field, and ++++, > 10
parasites/field) and at least 100 fields/slide were examined to rule out any negative thick film
slide. Enrollees in this group had no evidence of impaired consciousness, seizures, past history
of mental illness, meningitis or head injury.
Non-malaria subjects. Individuals with negative pLDH/HRP-2 RDT and no P. falciparum
parasitemia were recruited and classified as non-malaria subjects.
Relevant data relating to age, sex, complete blood counts and available medical history were
obtained from medical records as well as a survey administered in native language of the subjects (S1 Table). Venous blood samples from children (~5 mL) and adults (~8 mL) were collected after enrollment and prior to commencement of anti-malarial treatment. An aliquot was
transported to Noguchi Memorial Institute for Medical Research (NMIMR) and assessed by
fluorescence-activated cell sorting (FACS). Plasma, red blood cells and buffy coats were
obtained by centrifugation and stored at -80°C for later use.
Assessing Endothelial Progenitor Cell numbers and phenotype using FACS. Fortytwo randomly selected samples were chosen for FACS analysis using a systematic sampling
technique that picked every 12th subject. Selection of EPC was based on dual positive
CD34+CD309+ events [28]. The EPC population was defined as being CD45-CD34+CD309+
or CD45-CD34+CD133+, to account for immature EPC [18]. EPC were analyzed as previously
described [29]. Forward side scatter was used to eliminate debris and RBC. Gating strategy
included; selection of CD45- events from leukocyte Forward/Side Scatter dot plot, to exclude
lymphoid cells, followed by gating for CD34+CD309+ or CD34+CD133+ double positive events
for EPC quantification or CD34+CD284+ double positive events for EPC expression of TLR4
(S1 Fig). Aliquots of 200 μL of venous blood per reaction were incubated for 15 minutes in
the dark with mouse anti-human phycoerythrin (PE)-conjugated or fluorescein isothiocyanate
(FITC)-conjugated antibody pairs. EPC were isolated using specific antibody pairs; CD34FITC and CD304-PE (VEGFR2-PE). To assess TLR, specific antibody pair CD34-FITC and
CD284-PE (TLR4-PE) was used. Aliquots of cells incubated without antibodies or with appropriate isotype controls were used as controls. All antibodies were purchased from Miltenyi Biotec (Auburn, CA). After incubation, red blood cells were lysed with BD FACS lysing solution.
Remaining leukocytes, which included EPC populations, were washed with BD FACSFlow
solution, and immediately analyzed. Each analysis included 100,000 events, data compensation
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and analysis was performed using a BD FACScan System (BD Biosciences, San Diego, CA) and
FlowJo (version 10.6).
Quantification of plasma Heme, CXCL10 and Heme Oxygenase-1. Plasma was centrifuged for 30 min at room temperature at 1200xg to remove contaminating red blood cells.
Total heme was quantified using a colorimetric assay according to the manufacturer's instructions (BioAssay System, Hayward, CA).
To determine the relationship between malaria infection, plasma CXCL10 and HO-1
expression levels in malaria negative versus positive subjects and between free heme and
CXCL10 in vitro, we examined plasma in patients and supernatants from HBVEC and CD34+HSPC cell culture using commercially available Human CXCL10/IP-10 Quantikine ELISA kit
(R&D Systems, Minneapolis, MN) and Human HO-1 Enzyme Immunoassay kit (ENZO Life
Sciences, Plymouth Meeting, PA). CXCL10 and HO-1 levels were measured using optimal concentrations of standards and antibodies according to the manufacturer's instructions. The data
was analyzed at 450 nm wavelength using a Spectra Max 190 fluorescence micro plate reader
(Molecular Devices Corp., Sunnyvale, CA).
Cell Culture. Human brain microvascular endothelial cells (HBVEC) were cultured in
endothelial basal media supplemented with 2% Fetal Bovine Serum and growth factors
to obtain endothelial growth media (EGM-2, Lonza, Walkersville, MD). Human primary
CD34+-HSPC were isolated from human bone marrow mononuclear cells and include both
hematopoietic stem and progenitor cells (StemCell Technologies, Vancouver, Canada).
CD34+-HSPC’s were isolated using immunomagnetic positive selection from human adult
bone marrow. The cells were cultured in StemSpan SFEM II basal media supplemented with
StemSpan 100 expansion cocktail, both from StemCell Technologies. Both HBVEC and
CD34+-HSPC were passaged at 70–90% confluence, plated at a density of 2×105 cells/mL and
incubated at 37°C in 5% CO2 until ready for treatment.
TUNEL Assay. HBVEC and CD34+-HSPC were seeded at a density of 1×105 cells/mL in
96-well plates. Fresh heme was prepared in 0.02 M NaOH. Cells were serum-starved for 4 hr,
followed by exposure to 60 μM heme, vehicle (0.02 M NaOH) or positive control agent, 57 μM
camptothecin, (CPT) for 18 hr. The Guava easyCyte flow cytometry system was used to quantify apoptosis with the TUNEL Kit for Flow Cytometry (Millipore, Billerica, MA). Cells were
fixed and permeabilized using Guava TUNEL solution and apoptotic events were counted if
they emitted a nucleated cell fluorescent signal, and exhibited the forward light scatter (FSC)
intensity appropriate for a particle the size of a cell. Debris events with low FSC signal were not
counted. All population events were analyzed using CytoSoft version 2.0 software. Data corresponds to three experiments run in parallel.
RNA Extraction and qRT-PCR. Total RNA was isolated from HBVEC and CD34+-HSPC
using Qiagen RNeasy kit (Valencia, CA) and quantified using the Nanodrop N-1000 by Agilent
Biosystems (Santa Clara, CA). The Qiagen QuantiTech Reverse Transcription kit was used to
synthesize cDNA according to manufacturer instructions (Valencia, CA). The reverse transcription reactions were carried out in 20 μL volumes at 42°C for 15 min followed by 95°C for 3
min. TLR4 and CXCL10 expression were analyzed by quantitative RT-PCR and was performed
using iQ SYBER Green Supermix (Bio-Rad laboratories, Hercules, CA) in 25 μL reaction volumes with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as control. The CFX96 RealTime PCR System (Bio-Rad Laboratories, Hercules, CA) was used to perform qRT-PCR and
analyzed the cycle threshold data obtained using thermocycling conditions: 95°C for 15 min,
95°C for 15 sec, 55°C for 30 sec, and 72°C for 30 sec for 40 cycles. Primer sequences were as follows; CXCL10: (FP 5’- TGACTCTAAGTGGCATTCAAGG, RP 5’-CAAAATTGGCTTGC
AGGAAT), TLR4: (FP 5’- CAGGATGATGTCTGCCTCGC -3’, RP 5’- TTAGGAACCAC
CTCCACGCAG -3’), GAPDH: (FP 5’-GAAGGTGAAGGTCGGAGTC-3’, RP 5’-GAAGATG
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GTGARGGGATTTC-3’). The 2(-Delta Delta C(T)) method was used to analyze relative gene
expression data normalized to the housekeeping gene, GAPDH. Results are expressed as fold
change relative to housekeeping gene in treatment versus vehicle-treated cultures.
Statistical Analysis. Population distribution was determined using chi-squared test.
Experiments were performed in triplicate and p-values were determined using T-test, MannWhitney U-test, ANOVA or two-way ANOVA and Tukey’s post hoc comparisons where
appropriate. Data is presented as mean ± standard error or median and interquartile range
(IQR) unless otherwise stated. A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego California USA).

Results
A total of 575 participants were enrolled in the study; 147 non-malaria subjects and 428
malaria patients. There was a significant difference between the median age for non-malaria
subjects (13 years, IQR 4–14 years) and malaria patients (5 years, IQR 2–8 years), p < 0.0001
(Table 1). There were no significant differences in gender between the two groups (p = 0.07,
Table 1). Hematological indices showing significant differences between non-malaria and
malaria subjects included Hemoglobin (non-malaria, 12.3 gm/dL vs malaria, 11.8 gm/dL,
p < 0.0001), WBC (non-malaria, 7.1 gm/dL vs malaria, 6.0x103/mL, p < 0.0001) and platelet
(non-malaria, 235x103/mL vs malaria, 146x103/mL, p < 0.0001) (Table 1).

P. falciparum infection decreases frequency of circulating EPC
To determine the effect of P. falciparum infection on circulating EPC populations, we
measured frequency of EPC markers, both mature (CD45-CD34+VEGFR2+) and immature
(CD34+VEGFR2+CD133+), in leukocyte fractions of whole blood from 42 randomly selected
samples (8 non-malaria and 34 malaria) using FACS analysis. Randomization was accomplished using a systematic sampling technique that selected every 12th subject for recruitment
into the sub-study. The median frequencies of CD34+-HSPC and mature CD45-CD34+
VEGFR2+-EPC were significantly decreased in malaria patients relative to non-malaria subjects; 0.5 (IQR 0.3–0.9) in non-malaria vs. 0.2 (0.1–0.3) in malaria patients, p = 0.0006 and 0.3
(IQR 0.1–0.7) in non-malaria vs. 0.1 (IQR 0.1–0.2) in malaria patients, p = 0.02 (Fig 2A and
Table 1. Demographic and hematological characteristics.
Characteristic
Age (year)
Gender (% male)
Hemoglobin (gm/dL)

Non-Malaria Median (IQR) N = 147

Malaria Median (IQR) N = 428

p-value

13 (4–14)

5 (2–8)

<0.0001

54.4%

46.7%

0.07

12.3 (11.6–14.2)

11.8 (10.4–13.2)

<0.0001

7.1 (5.8–7.9)

6.0 (4.6–7.7)

<0.0001

Platelet (x103/mL)

235 (162–303)

146 (97–197)

<0.0001

EPC Frequency*

0.3 (0.1–0.7)

0.12(0.1–0.2)

0.018

WBC (x103/mL)

Dichotomous variables compared using χ2 and Fisher exact tests and continuous variables compared using Mann-Whitney tests. Values reported as
percent and number of observations for dichotomous variables or median and Interquartile Range (IQR) for continuous variables. There was a signiﬁcant
difference in median age however the age ranges for both the Non-Malaria and Malaria groups were the same. There were no signiﬁcant differences in
sex of the participants in each group.
*42 samples were randomly selected for EPC analysis; non-malaria = 8, malaria = 34.
doi:10.1371/journal.pone.0142328.t001
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Fig 2. CD34+ cell populations decreased in malaria. (A) CD34+ hematopoietic stem and progenitor cell populations are significantly decreased in malaria
patients. Median fluorescence intensity; 0.5 (IQR 0.3–0.9) in non-malaria, n = 8, vs. 0.2 (IQR 0.1–0.3) in malaria patients, n = 34, p = 0.0006. (B) Circulating
EPC numbers (CD45-CD34+VEGFR2+) are decreased in malaria patients by 1.7-fold compared with non-malaria. Median fluorescence intensity; 0.3 (IQR
0.1–0.7) in non-malaria, n = 8 vs malaria 0.1(IQR 0.1–0.2), n = 34, p = 0.02. Data represented as median frequency and Interquartile Range (IQR). MannWhitney tests were used to calculate p-value.
doi:10.1371/journal.pone.0142328.g002

2B. Immature EPC expressing CD34+VEGFR2+CD133+ are not reported due to very low numbers. Data are represented as the median numbers of EPC events per 100,000 leukocytes.

P. falciparum infection is associated with increased plasma heme, HO-1
and CXCL10 levels
In 2012, Liu et al. reported significant increases in heme-induced HO-1 and CXCL10 in plasma
in an experimental murine model of malaria and further confirmed their results in vitro [30].
This study and others demonstrated that free heme induces both HO-1 and CXCL10 expression in vitro and in vivo. To determine the levels of heme, HO-1 and CXCL10 in the plasma of
malaria patients, chromogenic heme assay and HO-1 and CXCL10 immunoassays were performed. There were significant increases in plasma concentrations of heme non-malaria
24.1 μM (IQR 19.1–29.7), malaria 26.9 μM (IQR 20.1–39.5), p < 0.0001, Fig 3A), HO-1
(non-malaria 1.8 ng/mL (IQR 1.2–2.3), malaria 2.5 ng/mL (IQR 1.1–5.1), p < 0.0001, Fig 3B)
and CXCL10 (non-malaria 180.4 pg/mL (IQR 101.1–328.6), malaria 705.7 pg/mL (IQR 459.0–
1154), p < 0.0001, Fig 4B) among malaria patients compared to non-malaria subjects
(Table 2).

P. falciparum infection increases expression of TLR4 in EPC and
plasma CXCL10 in vivo
In 2012, Liu et al. reported significant increases in plasma heme induced HO-1 and CXCL10 in
an experimental murine model of malaria and further confirmed their results in vitro [30].
This study and others demonstrate that free heme induces both HO-1 and CXCL10 expression
both in vitro and in vivo. FACS analysis was used to determine whether EPC exhibited altered
expression of TLR4 in non-malaria versus malaria subjects. Median fluorescence intensity of
TLR4 was assessed in 100,000 EPC events on a BD FACS Calibur. Statistical analysis of nonmalaria versus malaria subsets indicated there was a significant increase in the median fluorescence intensity of TLR4 (CD284) expression on EPC in malaria patients (Fig 4A, non-malaria
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Fig 3. Plasma heme and HO-1 levels increase in malaria patients. (A) Malaria patients have increased expression of plasma heme (p < 0.0001) and (B)
Heme Oxygenase-1 (HO-1) (p < 0.0001) compared to non-malaria subjects. Box plots representing medians with 25th and 75th percentiles, bars for 10th and
90th percentiles, and points for outliers of biomarker concentrations. Means indicated by (+) sign. Statistically significant p-values after Bonferroni adjustment
are shown, n = 411. Normal range of 0–60 μM heme and 0–4 ng/mL HO-1 observed in non-malaria subjects.
doi:10.1371/journal.pone.0142328.g003

subjects, 33.7 vs malaria patients, 40.9, p = 0.04). These results confirmed previous reports indicating that pro-inflammatory factors, such as heme and CXCL10 are significantly associated
with TLR4 expression in cells that modulate immunological responses [20, 31]. To determine
the levels of CXCL10 in the plasma of malaria patients, CXCL10 immunoassays were performed. There were significant increases in median plasma concentrations of CXCL10
[non-malaria subjects, 178.6 pg/mL (IQR 100.7–333.4), malaria patients, 698.3 pg/mL (IQR
453.8–1143), p < 0.0001, Fig 4B]

Fig 4. Malaria patients have increased expression of TLR4 and plasma CXCL10. (A) TLR4 Expression is increased in EPC of malaria patients: Median
Fluorescence Intensity in non-malaria subjects, 33.7 vs malaria patients, 40.9, p = 0.04. The EPC population was defined as being CD45-CD34+CD309+,
(non-malaria n = 8, malaria n = 34). (B) Plasma CXCL10 is significantly increased in malaria patients compared to non-malaria subjects (non-malaria
subjects, 178.6 pg/mL (IQR 100.7–333.4), malaria patients, 698.3 pg/mL (IQR 453.8–1143), p < 0.0001). Normal range of 49–811 pg/mL in non-malaria
subjects.
doi:10.1371/journal.pone.0142328.g004
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Table 2. Plasma Heme, Heme-Oxyenase-1 and CXCL10 quantification.
Non-Malaria N = 141*

Malaria N = 270†m

p-value

All ages

24.1 (19. 1–29.7)

26.9 (20.1–39.5)

<0.0001

age 16 years

24.3 (19.1–29.7)

29.3 (21.5–46.1)

<0.0001

age >16 years

23.7 (16.3–29.4)

20.5 (17.9–25)

0.2

All ages

1.8 (1. 2–2.3)

2.5 (1. 1–5.1)

<0.0001

age 16 years

1.9 (1.4–2.6)

2.6 (1.1–5.5)

0.0006

age >16 years

0.4 (0.2–0.9)

2.4 (0.9–4.3)

<0.0001

All ages

180.4 (101.1–328.6)

705.7 (459.0–1154)

<0.0001

age 16 years

198.1 (107.3–335.5)

666.2 (453.8–1024

<0.0001

age >16 years

121.6 (83.3–295.6)

1316 (534.4–1969)

<0.0001

Heme (μM)

Heme Oxygenase (ng/mL)

CXCL10 (pg/mL)

Continuous variables compared using Mann-Whitney test, values reported as median and Interquartile Range (IQR). Malaria subjects had signiﬁcantly
higher levels of heme, HO-1 and CXCL10 compared with non-malaria regardless of the age group.
*Among the 141 non-malaria subjects 89% (125/141) are 16 years of age and 11% (16/141) are >16 years of age.
†Among the 270 malaria subjects 83% (223/270) are 16 years of age and 17% (47/270) are >16 years of age.
doi:10.1371/journal.pone.0142328.t002

Heme induces apoptosis in human brain vascular endothelial and
CD34+ hematopoietic stem and progenitor cells
Previous studies demonstrated the functional role of free heme in human brain vascular endothelial cells (HBVEC) [8]. Here we confirm that heme (10–60 μM) decreases the viability of
HBVEC and CD34+-HSPC in a concentration-dependent manner (Fig 5). A significant reduction in viability was noted after 18h treatment with 40 μM heme (p = 0.04 vs. vehicle) and the
lethal dose for 50% (LD50) was obtained in both cell types with 60 μM heme, a physiologically
relevant concentration in hemolytic diseases [32, 33]. This time point and concentration were
used in subsequent experiments. Vehicle (0.02 M NaOH) did not significantly reduce cellular
viability at any time. The TUNEL assay was used to determine whether a significant level of
reduction in cell viability was due to apoptosis. Cells were treated with heme at LD50 doses and
significant increases in apoptosis were observed (measured as percentage of TUNEL positive
cells). Heme induced cell death via apoptosis in both HBVEC and CD34+-HSPC at 40 μM and
60 μM respectively (p = 0.04, Fig 5). 57 μM Camptothecin (CPT) was used as positive control.

Heme-induced TLR4 activation in HBVEC and CD34+-HSPC
Next we investigated the role of free heme in up-regulation of TLR4 mRNA in HBVEC and
CD34+-HSPC in vitro using qRT-PCR. TLR4 mRNA was up-regulated in HBVEC and CD34+HSPC when treated with heme at LD50 doses for 18 hr (Fig 6). TLR4 mRNA expression
increased 2.5-fold in HBVEC and approximately 2-fold in CD34+-HSPC. Data was analyzed
using student’s t-test; in HBVEC p = 0.002 and in CD34+-HSPC, p = 0.005. Having shown that
TLR4 expression was modulated by exposure to heme, we tested the functionality of TLR4 in
the presence of heme.
Heme-induced CXCL10 production in HBVEC and CD34+-HSPC is mediated by TLR4. To
confirm that TLR4 mediates production of CXCL10 in microvascular and progenitor cells
exposed to free heme, we assessed changes in CXCL10 protein and mRNA levels in HBVEC
and CD34+-HSPC in the presence and absence of both a TLR4 signaling inhibitor, anti-CD14,
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Fig 5. Heme induces apoptosis in HBVEC and CD34+-HSPC in vitro. Apoptosis was quantified using Guava TUNEL assay and analyzed by
fluorescence-activated cell sorting (FACS). Apoptosis was analyzed using analysis of variance followed by Tukey’s multiple comparisons test; In HBVEC p <
0.0001 in heme-treated versus NaOH vehicle, and in CD34+-HSPC p = 0.0004 in heme-treated versus NaOH vehicle. CPT is a potent inducer of apoptosis
used as positive control (p < 0.0001 in both cell types).
doi:10.1371/journal.pone.0142328.g005

and receptor binding antagonist, TAK-242, respectively. CD14 is a member of the LPS bacterial
pattern recognition receptor (PRR) complex that physically associates with TLR4 and induces
signal transduction and TAK-242 is a TLR4 antagonist that suppresses ligand-dependent
and -independent signaling. Induction of CXCL10 mRNA expression by heme was assessed
using qRT-PCR in both HBVEC and CD34+-HSPC. Expression of CXCL10 mRNA increased
7-fold in HBVEC and 2-fold in CD34+-HSPC when exposed to 60 μM heme for 18 hr, data
was analyzed using analysis of variance followed by Tukey’s multiple comparisons test (Fig
6A). In HBVEC, p < 0.0001 in heme-treated cells compared with vehicle and p = 0.0003 in
anti-CD14 plus heme treated cells compared to heme treated cells, and in CD34+-HSPC,
p = 0.02 in heme-treated cells compared with vehicle and p = 0.11 in anti-CD14 plus heme
treated cells compared to heme treated cells. Data is reported as mean fold-change relative to
GAPDH ± SD. The data indicates that in the presence of free heme, HBVEC and CD34+HSPC significantly increased their expression of CXCL10 mRNA, and blocking the extracellular domain of TLR successfully inhibits signal transduction leading to decreased CXCL10
mRNA expression in HBVEC.
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Fig 6. Heme mediates TLR expression in vitro. TLR4 mRNA expression was analyzed using student’s t-test. In HBVEC p = 0.002 in heme-treated versus
NaOH vehicle and in CD34+-HSPC p = 0.005 in heme-treated versus NaOH vehicle. Data reported as mean fold-change relative to GAPDH.
doi:10.1371/journal.pone.0142328.g006

CXCL10 protein expression is TLR4 dependent in supernatants of HBVEC and CD34+HSPC in vitro. To determine whether the increase in CXCL10 protein expression was mediated
through TLR4, we used TAK-242 to assess changes in expression of CXCL10 in the presence of
60 μM heme. HBVEC and CD34+-HSPC were treated with or without TAK-242 TLR4 antagonist for 1 hour prior to 18 hr heme treatment. CXCL10 protein expression was analyzed in
60 μM heme-treated versus vehicle-treated cells and TAK-242 plus 60 μM heme-treated versus
vehicle-treated cells using analysis of variance followed by Tukey’s multiple comparisons test
(Fig 7B). In HBVEC, p = 0.04 in heme-treated cells compared with vehicle and p = 0.01 in
TAK-242 plus heme-treated cells compared to heme treated cells. In CD34+-HSPC, p = 0.04 in
heme-treated cells compared with vehicle and p = 0.03 in TAK-242 plus heme-treated cells
compared to heme treated cells. Data is reported as mean CXCL10 concentration ± SD. These
data indicate that in the presence of free heme, HBVEC and CD34+-HSPC significantly
increase expression of CXCL10 protein, and antagonist binding of TLR4 successfully inhibits
signal transduction leading to decreased CXCL10 expression in HBVEC and CD34+-HSPC.
This confirmed the functional role of TLR4 in heme-induced CXCL10 production.
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Fig 7. Heme-mediated stimulation of CXCL10 expression is TLR4 dependent. (A) CXCL10 mRNA expression is TLR4 dependent in HBVEC and
CD34+-HSPC in vitro. CXCL10 mRNA expression was analyzed using analysis of variance followed by Tukey’s multiple comparisons test. In HBVEC and
CD34+-HSPC, heme-treatment increased CXCL10 expression compared to vehicle (p < 0.0001 and 0.02, respectively). CXCL10 mRNA expression was
decreased in the presence of anti-CD14 compared with heme alone (p = 0.0003 and p = 0.11, respectively). Data reported as mean fold-change relative to
GAPDH. (B) CXCL10 expression is TLR4 dependent in supernatants of HBVEC and CD34+-HSPC in vitro. CXCL10 protein expression was analyzed using
analysis of variance followed by Tukey’s multiple comparisons test. In HBVEC and CD34+-HSPC, heme-treatment increased CXCL10 expression compared
to vehicle (p = 0.04 and 0.04, respectively). CXCL10 expression was decreased in the presence of TAK-242 compared with heme alone (p = 0.01, and 0.03,
respectively). The 2(-Delta Delta C(T)) method was used to analysis relative gene expression data normalized to housekeeping gene, GAPDH, which was
unaffected by experimental. Results are expressed as fold change relative to housekeeping gene in treatment versus vehicle-treated cultures.
doi:10.1371/journal.pone.0142328.g007

Discussion
We hypothesized that EPC depletion during malaria pathogenesis is a function of hemeinduced apoptosis mediated by CXCL10 induction and Toll-like receptor (TLR) activation. In
this study, individuals with malaria have significantly lower levels of EPC than observed in
non-malaria. In addition, plasma levels of heme, heme oxygenase-1 (HO-1) and CXCL10 were
significantly increased compared with non-malaria subjects.
We have previously shown that free heme is a potent apoptotic factor as well as inducer of
the pro-inflammatory chemokine CXCL10 in microvasculature (HBVEC) in vitro and in
murine models of experimental cerebral malaria (ECM) [11, 30]. Free heme in the plasma is
generated during intravascular hemolysis when Plasmodium parasites scavenge erythrocytic
hemoglobin. It has also been reported that free heme induces oxidative free radicals, leading to
severe microvascular damage in sickle cell disease through induction of TLR4 [22, 34, 35]. Circulating endothelial progenitor cells play an important role in the repair and regeneration of
damaged vascular endothelium as well as neovascularization in cerebrovascular disease [15,
36–40]. These cells are derived from CD34+ hematopoietic stem and progenitor cells, and these
stem cell populations are depleted in individuals with severe malaria by an unknown mechanism [25, 41]. Heme is cytoprotective to human vascular endothelial cells at low concentrations
when it induces the heme-neutralizing enzyme, HO-1, but is cytotoxic at very high concentrations [42–44]. Decreases in EPC were associated with increased heme and CXCL10 levels in
addition to increased expression of TLR4 in malaria patients. To further establish the role of
heme in malaria pathogenesis, we assessed the plasma levels of the heme-degrading enzyme
HO-1 versus non-malaria subjects, and found that indeed they were increased as well. This
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suggests that in the pathogenesis of malaria, HO-1 has the potential to serve as an effective
marker of heme toxicity and malaria severity.
The role of free heme in EPC depletion during severe malaria pathogenesis is poorly understood; therefore we explored the possibility that depletion of these endothelial cell precursors is
mediated by TLR4 [19, 21, 45, 46]. In both human and murine malaria infection, increases in
heme, CXCL10 and TLR4 and TLR9 have been shown to regulate the host immune response to
Plasmodium infection [47–49]. In the present study, we have shown that heme-induced expression of CXCL10 and apoptosis was mediated by TLR4 in HBVEC and CD34+-HSPC. This confirmed in vivo observations of increased TLR4 expression in EPC populations in the presence
of plasma heme and CXCL10 elevation. In addition, the TLR4 antagonist, TAK-242, dampened
CXCL10 production in vitro in the presence of heme. Therefore, we propose a pathophysiological mechanism whereby heme mediates the TLR4 signaling pathway, resulting in overproduction of cytotoxic CXCL10. Thus depletion of EPC is a consequence of heme-induced CXCL10
production and TLR4-mediated apoptosis.
This study confirmed previous reports of the role of toll-like receptor activation in parasitic
and inflammatory diseases. For example, glycosylphosphatidylinositol anchors from the protozoan parasite Trypanasoma cruzi parasites are potent activators of TLR2 in both mice and
humans and prolonged exposure to low doses of TLR4 activating LPS decreases the repopulating potential of murine hematopoietic stem and progenitor cells and increases inflammatory
cytokine production [21, 50, 51]. Additionally, bone marrow mononuclear and CD34+ cells
from individuals with myelodysplastic syndromes, express increased levels of TLR4 when compared to the constitutive expression of TLR4 in the absence of these hematological syndromes
[52]. It is also widely accepted, that in P. falciparum infection, there is a subset of individuals
that have polymorphisms in TLR4 and TLR9 that have been linked to severe disease in both
CM and ECM [47, 53, 54]. We have shown that integral components of the BBB, specifically
HBVEC and CD34+-HSPC, are activated to increase expression of TLR4 in addition to excess
CXCL10 production in the presence of increased heme, which mimics in vivo conditions in
malaria. The expression of TLR4 by these populations makes them susceptible to the inflammatory effects of deleterious TLR4 activators TNFα and IFNγ, both of which are up-regulated
in malaria [8, 20, 55]. In fact, knockout of MyD88, an adapter protein used by TLR4 to activate
transcription factor NF-κB, resulted in decreased gene expression of these factors in the ECM
mouse model [55, 56].
HBVEC showed significant reductions in expression of CXCL10 in the presence of the
TLR4-blocking agent anti-CD14 in vitro conditions, though decreases in CXCL10 expression
in CD34+-HSPC did not reach statistical significance. These findings indicate a resilience of
CD34+-HSPC to receptor-mediated TLR4 signaling when compared to HBVEC. The high activation threshold in CD34+-HSPC may be cytoprotective and would explain why HBVEC had
enhanced responses to heme, while CD34+-HSPC seemed to have dampened immunological
response though susceptible to its apoptotic effects. Another possible explanation is that the
high rate at which these cells undergo apoptosis in the presence of heme prevented detection of
CXCL10 transcript in the presence or absence of TLR4 inhibitors.
Although this study assessed the role of heme in depleting EPC directly, another potential
scenario is that mobilization of EPC from the bone marrow may be inhibited or inactivated in
the presence of increased heme or other unknown cytotoxic factors [57, 58]. These circumstances would prevent detection of EPC populations using flow cytometric analysis of progenitor cell markers, a pitfall of this study. Lastly, expression of inflammatory receptors such as
TLR4, would result in increased migration of EPC towards cites of localized endothelial damage, inducing activation, differentiation and potential sequestration of EPC from circulation, as
reported elsewhere [20, 59]. Therefore, the intriguing question is whether EPC being depleted
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occurs due to cytotoxicity of free heme, sequestration or rapid activation and differentiation in
the presence of increased serum CXCL10? We have shown that decreased bioavailability of
EPC in malaria patients is due, in part, to heme toxicity, mediated by expression of TLR4 and
further exacerbated by an exaggerated host inflammatory response due to excess production of
CXCL10.
In this study we have shown that heme-induced, TLR4-mediated CXCL10 expression contributes significantly to depletion of HBVEC and CD34+-HSPC. Our results indicate that free
heme is a major contributor to severe malaria pathophysiology by inducing apoptosis in
HBVEC and CD34+-HSPC, which are vital BBB cellular components.
One aspect of malaria pathogenicity, the role of polymorphisms in human CXCL10, HO-1
and TLR genes have been reported but were not assessed here [47, 60–62]. In addition, age has
been suggested to play a role in malaria pathogenesis, however, in our study age did not play a
role in the expression of heme, CXCL10 and HO-1. These indices were higher in both adult
and children malaria patients than non-malaria subjects of the same age group (Table 2).
Therefore, the observed variations in host expression of these factors may be attributed to
genetic variation inherent in sub-Saharan Africa. Further studies are underway to elucidate the
precise mechanism(s) and/or genetic influences controlling EPC depletion in malaria in this
geographic region.
Currently, there are few if any specific and sensitive biomarkers for prognosis of fatal
malaria. Several host and parasite indicators of malaria infection have been identified as predictors of disease prognosis (from mild uncomplicated to severe malaria) including angiopoietins,
elevated CXCL10 serum levels, CXCL10 polymorphisms and free heme [61, 63, 64]. Recently,
many studies have investigated the use of EPC depletion as a potential biomarker for cancer
and various inflammatory diseases, including malaria [65, 66]. Here we propose a TLR4-mediated role by which mature EPC are reduced in malaria patients. This study acknowledges
that depletion of EPC is an important facet of malaria pathogenesis and identifies heme,
CXCL10, TLR4 and circulating EPC levels as potential biomarkers for identification of individuals at risk of developing severe forms of the disease.
Heme induces production of apoptotic and inflammatory host factors, including CXCL10,
and exacerbates malaria pathogenesis [11, 12]. Previous reports address the role of hemeinduced CXCL10 in exacerbating severe malaria, and the vasculo-protective effects of HO-1’s
ability to mediate CXCL10 expression [11, 43, 44, 67, 68]. Therefore potential adjunctive therapies would likely include bolstering HO-1 production or decreasing the amount of free heme
in the plasma, thereby preventing the overexpression of angiostatic and inflammatory CXCL10
production. Another potential therapy would involve the use of hemopexin or haptoglobin in
adjunctive therapies capable of quenching excessive free heme in malaria patients [69–72].
Lastly, blockage of TLR4 expression in brain microvasculature and circulating EPC would aide
in decreasing the cytotoxic effects of heme by reducing its receptor-activated, apoptotic effects
[20, 22]. In conclusion, this study has demonstrated that heme plays an important role in the
viability of vital host cells such as HBVEC and EPC and should be further assessed in a wider
range of populations and other brain microvascular supporting cell types for use in development of novel therapeutics in the prevention and treatment of severe malaria.

Supporting Information
S1 Fig. Gating strategy and selection of CD34+ cell populations from whole blood leukocyte
fraction. The CD34+-HSPC population was defined as CD45-CD34+ and the EPC population
was defined as CD45-CD34+CD309+ from Forward Scatter/Side Scatter upon elimination of
debris and RBC. Gating strategy included selection of CD45- events followed by gating for
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CD34+ or CD34+CD309+ double positive events.
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